4 results match your criteria: "Kohnodai Hospital National Center for Global Health and Medicine Ichikawa Chiba Japan.[Affiliation]"
No change in the severity of eating disorders in Japanese children during the COVID-19 pandemic.
PCN Rep
September 2024
Department of Child and Adolescent Psychiatry, Kohnodai Hospital National Center for Global Health and Medicine Ichikawa Chiba Japan.
Article Synopsis
- The review highlights the importance of evaluating mental health information and activities by the CDC for application in Japan, especially for the new health center.
- The Japanese government is focusing on the New Center for Health Control to tackle children's mental health issues amid the ongoing health crisis.
- The findings stress the critical need to prioritize children's mental health and develop effective strategies to address the long-term impacts of the COVID-19 pandemic.
Comparison of severe hyponatremia in patients with and without psychiatric diseases: A single-center retrospective study.
PCN Rep
March 2023
Department of Internal Medicine, Kohnodai Hospital National Center for Global Health and Medicine Ichikawa Chiba Japan.
Aims: Hyponatremia is a common electrolyte disorder. The severe hyponatremia has a mortality rate of 4%-40%. Psychiatric patients are likely to develop the condition because of polydipsia or the adverse effects of antipsychotics.
View Article and Find Full Text PDFDecision aid development and its acceptability among adults with attention-deficit/hyperactivity disorders regarding treatment discontinuation after remission.
PCN Rep
December 2022
Department of Child and Adolescent Psychiatry, Faculty of Medicine Hokkaido University Sapporo Hokkaido Japan.
Aim: Current clinical guidelines for attention-deficit/hyperactivity disorder (ADHD) put shared decision making (SDM) at the center of care. However, there remain challenges in SDM in ADHD management, particularly regarding the decision to continue or discontinue medication after ADHD remission in adult patients. We aimed to develop a decision aid (DA) for adult patients with ADHD regarding the continuation or discontinuation of their ongoing ADHD medications after they have attained remission.
View Article and Find Full Text PDF